A Cornell-led collaboration devised a potentially low-cost method for producing antibodies for therapeutic treatments: bioengineered bacteria with an overlooked enzyme that can help monoclonal antibodies boost their immune defenses.
Read the story in the Cornell Chronicle.
Ask an ambassador: How my first-year writing seminar enriched my four years
A&S Student Ambassador
